liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease
Karolinska University Hospital, Stockholm, Sweden.
Östergötlands Läns Landsting, Centre for Diagnostics, Department of Clinical Chemistry.
Molde Hospital HNR, Norway .
Sahlgrenska University Hospital, Gothenburg, Sweden.
Show others and affiliations
2012 (English)In: Acta Neurologica Scandinavica, ISSN 0001-6314, E-ISSN 1600-0404, Vol. 126, no 6, e29-e33 p.Article in journal (Refereed) Published
Abstract [en]

Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, andgt;= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months.

Place, publisher, year, edition, pages
John Wiley & Sons, 2012. Vol. 126, no 6, e29-e33 p.
Keyword [en]
movement disorders, Parkinsons disease, quality of life, treatment
National Category
Engineering and Technology
URN: urn:nbn:se:liu:diva-85843DOI: 10.1111/j.1600-0404.2012.01689.xISI: 000310545400001OAI: diva2:573293

Funding Agencies|Abbott Laboratories, Abbott Park, IL, USA||Abbott||Swedish Parkinsons Disease Foundation||Swedish Research Council||Ostergotland County Council||Liber AB||Kibion AB||Selanders Foundation||Swedish Society for Medical Research||Uppsala University||

Available from: 2012-11-30 Created: 2012-11-30 Last updated: 2012-12-05

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Dizdar, Nil
By organisation
Department of Clinical Chemistry
In the same journal
Acta Neurologica Scandinavica
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 39 hits
ReferencesLink to record
Permanent link

Direct link